Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-center, Randomized, Double-blind, Comparative Study to Evaluate the Clinical Efficacy and Safety of QL1206 and Xgeva in Patients With Bone Metastases From Solid Tumors

Next Previous
X
Search
Trial Profile

A Multi-center, Randomized, Double-blind, Comparative Study to Evaluate the Clinical Efficacy and Safety of QL1206 and Xgeva in Patients With Bone Metastases From Solid Tumors

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 24 Feb 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Denosumab (Primary)
  • Indications Bone metastases; Breast cancer; Lung cancer; Solid tumours
  • Focus Registrational; Therapeutic Use
  • Sponsors Qilu Pharmaceutical

    • Most Recent Events

    • 12 Feb 2023 Results reporting efficacy, safety, and pharmacokinetics data published in the BioDrugs
    • 18 Nov 2022 Results (n = 311) of these analyses in breast cancer subgroup, presented at the 13th European Breast Cancer Conference.
    • 09 Aug 2022 Results of lung cancer cohort assessing efficacy and safety of denosumab biosimilar QL1206 versus denosumab in bone metastatic tumor, presented at the 2022 World Conference on Lung Cancer.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top